10-K
Annual Report
ACTINIUM PHARMACEUTICALS, INC.
ATNM
NYSEAMER
CIK: 1388320
File #: 001-36374
Balance Sheet
30 line items · 2 periods
XBRL
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
Assets | ||
Current Assets: | ||
Cash and cash equivalents | 47,998,000 | 72,904,000 |
Prepaid expenses and other current assets | 1,383,000 | 1,602,000 |
Total Current Assets | 49,381,000 | 74,506,000 |
Property and equipment, net of accumulated depreciation of $1,064 and $891 | 295,000 | 364,000 |
Restricted cash – long term | 335,000 | 324,000 |
Operating lease right-of-use assets | 1,754,000 | 1,685,000 |
Finance leases right-of-use assets | 10,000 | 20,000 |
Total Assets | 51,775,000 | 76,899,000 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 7,247,000 | 7,568,000 |
Operating leases current liability | 711,000 | 569,000 |
Finance leases current liability | 11,000 | 11,000 |
Total Current Liabilities | 7,969,000 | 8,148,000 |
Long-term license revenue deferred | 35,000,000 | 35,000,000 |
Long-term operating lease obligations | 972,000 | 984,000 |
Long-term finance lease obligations | — | 9,000 |
Total Liabilities | 43,941,000 | 44,141,000 |
Stockholders’ Equity: | ||
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 shares issued and outstanding at December 31, 2025 and 2024, respectively | 31,000 | 31,000 |
Additional paid-in capital | 417,536,000 | 408,553,000 |
Accumulated other comprehensive loss | (20,000) | — |
Accumulated deficit | (409,713,000) | (375,826,000) |
Total Stockholders’ Equity | 7,834,000 | 32,758,000 |
Common Stock | 31,000 | 31,000 |
Additional Paid-In Capital | 417,536,000 | 408,553,000 |
Accumulated Other Comprehensive Loss | (20,000) | — |
Accumulated Deficit | (409,713,000) | (375,826,000) |
Total Liabilities and Stockholders’ Equity | 51,775,000 | 76,899,000 |